Trial · NCT00441792
The Effect of Etomidate on Patient Outcomes After Single Bolus Doses
NCT00441792, Not applicable, Completed, Advocate Hospital System; results first posted 2012-04-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effect of Etomidate on Patient Outcomes After Single Bolus Doses. Trials, record NCT00441792. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00441792
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effect of Etomidate on Patient Outcomes After Single Bolus Doses
- NCT number
- NCT00441792
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 122 participants, actual
- Lead sponsor
- Advocate Hospital System
- Conditions
- Sepsis, Trauma
- Interventions
- Etomidate, midazolam
- First posted
- 2007-03-01
- Last updated
- 2012-04-11
- Results first posted
- 2012-04-06
- Limitations and caveats
Because of limitations in the availability of study investigators and pharmacists, we were unable to enroll all potentially eligible patients, raising the possibility that our study sample was not representative of our entire patient population.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Length of Stay | time in days of hospitalization | The primary outcome of the study was hospital length of stay. |
| Secondary | Mortality | Duration of hospitalization. | In-hospital mortality. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Mortality | Duration of hospitalization. | All patients entering into the study were analyzed on an intent to treat basis. | percentage of patients dying | NUMBER |
| PRIMARY | Length of Stay | time in days of hospitalization | All patients entering into the study were analyzed on an intent to treat basis. | days | MEDIAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mortality | Midazolam | 36 | 95% Confidence Interval 24 to 49 | percentage of patients dying | |
| Mortality | Etomidate | 43 | 95% Confidence Interval 30 to 56 | percentage of patients dying | |
| Length of Stay | Midazolam | 9.5 | Inter-Quartile Range 4.6 to 16 | days | |
| Length of Stay | Etomidate | 7.3 | Inter-Quartile Range 3.1 to 13 | days |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Midazolam | 59 | |
| Overall Study | STARTED | Etomidate | 63 | |
| Overall Study | COMPLETED | Midazolam | 59 | |
| Overall Study | COMPLETED | Etomidate | 61 | |
| Overall Study | NOT COMPLETED | Midazolam | 0 | |
| Overall Study | NOT COMPLETED | Etomidate | 2 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Midazolam | ||
| Total, all-cause mortality | Etomidate | ||
| Total, other adverse events | Midazolam | 0 | 59 |
| Total, other adverse events | Etomidate | 0 | 61 |
| Total, serious adverse events | Midazolam | 0 | 59 |
| Total, serious adverse events | Etomidate | 0 | 61 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 20828877 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Midazolam vs Etomidate: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00441792
GET https://conductscience.org/api/trials/v1/NCT00441792/registered